Santen Pharmaceutical Co (4536) Stock Statistics & Valuation Metrics

Santen Pharmaceutical Co has a market cap or net worth of ¥711.16B. The enterprise value is ¥529.35B.

Santen Pharmaceutical Co has 322,290,160 shares outstanding. The number of shares has decreased by -2.65% in one year.

Santen Pharmaceutical Co’s return on equity (ROE) is 0.13 and return on invested capital (ROIC) is 13.05%.

The current PE Ratio of Santen Pharmaceutical Co is 19.6. Santen Pharmaceutical Co’s PEG ratio is 1.62.

In the last 12 months, Santen Pharmaceutical Co had revenue of 300.00B and earned 36.26B in profits. Earnings per share was 103.98.

In the last 12 months, operating cash flow was 46.19B and capital expenditures -7.37B, giving a free cash flow of 38.82B billion.

Santen Pharmaceutical Co pays an annual dividend of ¥21, resulting in a dividend yield of 2.3%

Santen Pharmaceutical Co upcoming earnings date is Aug 6, 2026, TBA (Confirmed).

Santen Pharmaceutical Co as a current ratio of 2.58, with Debt / Equity ratio of ―

In the past 12 months, Santen Pharmaceutical Co has paid 11.63B in taxes.

Santen Pharmaceutical Co EV to EBITDA ratio is 6.54, with an EV/FCF ratio of 8.02.

Santen Pharmaceutical Co has ¥63.56B in cash and marketable securities with ¥0.00 in debt, giving a net cash position of ¥27.93B billion.

Gross margin is ―, with operating margin of 18.74%, and net profit margin of 12.09%.

The average price target for Santen Pharmaceutical Co is ―, which is 11.43% higher than the current price. The consensus rating is ―